|
1
|
Sato T, Han F and Yamamoto A: The biology
and management of uveal melanoma. Curr Oncol Rep. 10:431–438. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Jia R, Wang J, Xu X, Yao Y, Ge S
and Fan X: Targeted silencing of MART-1 gene expression by RNA
interference enhances the migration ability of uveal melanoma
cells. Int J Mol Sci. 14:15092–15104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yousef YA and Alkilany M:
Characterization, treatment, and outcome of uveal melanoma in the
first two years of life. Hematol Oncol Stem Cell Ther. 8:1–5. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sagoo MS, Harbour JW, Stebbing J and
Bowcock AM: Combined PKC and MEK inhibition for treating metastatic
uveal melanoma. Oncogene. 33:4722–4723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pereira PR, Odashiro AN, Lim LA, Miyamoto
C, Blanco PL, Odashiro M, Maloney S, De Souza DF and Burnier MN Jr:
Current and emerging treatment options for uveal melanoma. Clin
Ophthalmol. 7:1669–1682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Okazaki IJ and Moss J:
Mono-ADP-ribosylation: A reversible posttranslational modification
of proteins. Adv Pharmacol. 35:247–280. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bourne HR: ADP-Ribosylating toxins and G
proteins. Insights into signal transduction. Joel Moss and Martha
Vaughan, Eds. American society for microbiology, Washington, DC,
1990. xviii, 567 pp., illus. $79; to ASM members, $69. Science.
250:841–842. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ludden PW: Reversible ADP-ribosylation as
a mechanism of enzyme regulation in procaryotes. Mol Cell Biochem.
138:123–129. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Isa M A, Abu-Rafea B, Al-Asiri S,
Al-Motawa J, Almady K and Alwaznah R: Ovarian stimulation
medications and patients' responses as prognostic factors in
IUI-treated infertile Saudi patients. Iran J Reprod Med.
12:493–498. 2014.PubMed/NCBI
|
|
11
|
Shi W, Gong P, Fan J, Yan YH, Ni L, Wu X,
Cui G, Wu X, Gu X and Chen J: The expression pattern of
ADP-ribosyltransferase 3 in rat traumatic brain injury. J Mol
Histol. 43:37–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rajender S, Avery K and Agarwal A:
Epigenetics, spermatogenesis and male infertility. Mutat Res.
727:62–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao M, Tang Y, Chen WW, Wang YL, Yang L,
Li X, Song GL and Kuang J: Tubb3 regulation by the Erk and Akt
signaling pathways: A mechanism involved in the effect of arginine
ADP-ribosyltransferase 1 (Art1) on apoptosis of colon carcinoma
CT26 cells. Tumour Biol. 37:2353–2363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bi J, Li P, Li C, He J, Wang Y, Zhang H,
Fan X, Jia R and Ge S: The SDF-1/CXCR4 chemokine axis in uveal
melanoma cell proliferation and migration. Tumour Biol.
37:4175–4182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Chang W, Dynek JN and Smith S: NuMA is a
major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis.
Biochem J. 391:177–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Momii A and Koide SS: Adenosine
diphosphate-ribosyltransferase activity in permeabilized mouse
testicular cells. Arch Biochem Biophys. 214:628–633. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okada H, Tajima A, Shichiri K, Tanaka A,
Tanaka K and Inoue I: Genome-wide expression of azoospermia testes
demonstrates a specific profile and implicates ART3 in genetic
susceptibility. PLoS Genet. 4:e262008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Friedrich M, Grahnert A, Klein C, Tschöp
K, Engeland K and Hauschildt S: Genomic organization and expression
of the human mono-ADP-ribosyltransferase ART3 gene. Biochim Biophys
Acta. 1759:270–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cools-Lartigue JJ, McCauley CS, Marshall
JC, Di Cesare S, Gregoire F, Antecka E, Logan P and Burnier MN:
Immunomagnetic isolation and in vitro expansion of human uveal
melanoma cell lines. Mol Vis. 14:50–55. 2008.PubMed/NCBI
|
|
21
|
Nareyeck G, Zeschnigk M, Prescher G,
Lohmann DR and Anastassiou G: Establishment and characterization of
two uveal melanoma cell lines derived from tumors with loss of one
chromosome 3. Exp Eye Res. 83:858–864. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng H, Terai M, Kageyama K, Ozaki S,
McCue PA, Sato T and Aplin AE: Paracrine effect of NRG1 and HGF
drives resistance to MEK inhibitors in metastatic uveal melanoma.
Cancer Res. 75:2737–2748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carvajal RD, Sosman JA, Quevedo JF, Milhem
MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J,
Lawson DH, et al: Effect of selumetinib vs. chemotherapy on
progression-free survival in uveal melanoma: A randomized clinical
trial. JAMA. 311:2397–2405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Landreville S, Agapova OA, Matatall KA,
Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone
deacetylase inhibitors induce growth arrest and differentiation in
uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Wang H, Zhang J, Qian G, Niu B,
Fan X, Lu J, Hoffman AR, Hu JF and Ge S: Enhanced therapeutic
efficacy by simultaneously targeting two genetic defects in tumors.
Mol Ther. 17:57–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu S, Luo Q, Cun B, Hu D, Ge S, Fan X and
Chen F: The pharmacological NF-κB inhibitor BAY11-7082 induces cell
apoptosis and inhibits the migration of human uveal melanoma cells.
Int J Mol Sci. 13:15653–15667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Paraoan L, Gray D, Hiscott P,
Garcia-Finana M, Lane B, Damato B and Grierson I: Cathepsin S and
its inhibitor cystatin C: Imbalance in uveal melanoma. Front Biosci
(Landmark Ed). 14:2504–2513. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johansson Hertzman C and Brage Egyhazi S:
BRAF inhibitors in cancer therapy. Pharmacol Ther. 142:176–182.
2014. View Article : Google Scholar : PubMed/NCBI
|
